Loading…
Kazia Therapeutics Limited is projected to rise to $14.98 by 2027, a +10% move from its current price of $13.56. KZIA is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 14 | $13.09 | $13.56 | $14.06 | +0.03% |
| Jul 15 | $12.90 | $13.57 | $14.27 | +0.05% |
| Jul 16 | $12.75 | $13.57 | $14.44 | +0.08% |
| Jul 17 | $12.63 | $13.57 | $14.58 | +0.10% |
| Jul 18 | $12.53 | $13.58 | $14.71 | +0.13% |
| Jul 19 | $12.44 | $13.58 | $14.83 | +0.15% |
| Jul 20 | $12.35 | $13.58 | $14.94 | +0.18% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $12.35 | $13.58 | $14.94 | +0.18% |
| Week 2 | $11.90 | $13.61 | $15.56 | +0.36% |
| Week 3 | $11.57 | $13.63 | $16.07 | +0.54% |
| Week 4 | $11.30 | $13.66 | $16.51 | +0.72% |
| Week 5 | $11.07 | $13.68 | $16.92 | +0.90% |
| Week 6 | $10.86 | $13.71 | $17.29 | +1.08% |
| Week 7 | $10.68 | $13.73 | $17.65 | +1.26% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in Israel. The company’s lead development candidate is paxalisib, a brain-penetrant inhibitor of the phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, which is in Phase II/III clinical trial for the treatment of glioblastoma; in Phase II trial to treat isocitrate dehydrogenase-mutant glioma, primary central nervous system (CNS) lymphoma, diffuse intrinsic pontine glioma, and brain metastases; and in pre-clinical studies to treat triple-negative breast cancer, as well as for the treatment of atypical rhabdoid/teratoid tumors. It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3 that is in Phase I clinical trial to treat advanced solid tumors and ovarian cancer.
The company has collaborations with the Australian and New Zealand Children’s Haematology/Oncology Group, Genentech Inc., Global Coalition for Adaptive Research, Vivesto AB, Simcere Pharmaceutical Group Ltd, Evotec SE, Sovargen Co., Ltd, and QIMR Berghofer Medical Research Institute. Kazia Therapeutics Limited was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.
Kazia Therapeutics Limited trades in the healthcare sector as an oncology-focused biotechnology company. The stock is currently priced at $13.25 per share and has a market capitalization of $151.41M, with a market rank of 3910. The near-term price outlook reflects bullish technical sentiment, with the price pattern supported by a bullish setup in the broader price action.
The multi-year forecast shows growing upside over time, with higher average prices and bullish sentiment from 2027 onward.
A major floor 47.5% below — a decisive break under it would weaken the trend.
The nearest floor, 19.2% below — buyers have tended to step in here.
The nearest ceiling, 8.3% above — a clean break opens room to run.
A major ceiling 23.9% above — clearing it would confirm fresh momentum.
Key KZIA support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of KZIA market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $13.04 | Buy | $13.21 | Buy |
| MA 10 | $13.46 | Buy | $13.34 | Buy |
| MA 20 | $13.73 | Sell | $13.34 | Buy |
| MA 50 | $13.16 | Buy | $12.66 | Buy |
| MA 100 | $10.82 | Buy | $11.42 | Buy |
| MA 200 | $9.31 | Buy | $10.31 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 52.89 | Neutral |
| Stoch RSI (14) | 47.99 | Neutral |
| CCI (20) | -20.68 | Neutral |
| Williams %R (14) | -50.67 | Info |
| MACD (12,26,9) | -0.15 | Sell |
| ROC (12) | -7.69 | Sell |
| Bollinger %B (20,2) | 0.43 | Neutral |
| Stochastic %K (14) | 49.33 | Neutral |
| TRIX (15) | 0.29 | Buy |
| Awesome (5,34) | -0.01 | Sell |
| Ultimate (7,14,28) | 44.25 | Neutral |
| Momentum (10) | -0.36 | Sell |
| Aroon Osc (25) | 52.00 | Buy |
| Hull MA (9) | 12.79 | Buy |
| ADX (14) | 13.08 | Neutral |
| ATR (14) | 0.43 | Info |
The near-term technical picture is bullish, supported by a neutral RSI reading and constructive moving averages. RSI(14) is 50, with the SMA50 at $13.04 and the SMA200 at $9.18. A key support level sits at $10.95 and a resistance at $14.69, framing a 30-day price range from $10.34 to $16.98.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $5.00 | $13.56 | $17.42 | 0% | Neutral | |
| $11.58 | $14.98 | $20.70 | +10% | Neutral | |
| $11.35 | $15.26 | $22.09 | +13% | Neutral | |
| $14.27 | $19.79 | $29.70 | +46% | Bullish | |
| $16.99 | $24.24 | $37.49 | +79% | Bullish | |
| $18.43 | $26.99 | $42.84 | +99% | Bullish | |
| $20.91 | $31.38 | $51.00 | +131% | Bullish | |
| $18.81 | $28.88 | $47.93 | +113% | Bullish | |
| $18.85 | $29.58 | $50.05 | +118% | Bullish | |
| $23.49 | $37.65 | $64.85 | +178% | Bullish | |
| $31.07 | $54.93 | $101.92 | +305% | Bullish | |
| $59.86 | $126.19 | $260.51 | +831% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $5.00 | $13.56 | $16.31 | +0.00% |
| August 2026 | $11.74 | $13.98 | $17.17 | +3.09% |
| September 2026 | $11.55 | $13.88 | $17.29 | -0.71% |
| October 2026 | $10.89 | $13.19 | $16.63 | -4.98% |
| November 2026 | $10.78 | $13.15 | $16.75 | -0.32% |
| December 2026 | $11.04 | $13.55 | $17.42 | +3.05% |
Click any year to see its month-by-month KZIA forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, KZIA is projected to trade between $5.00 and $17.42, averaging $13.56 — a potential gain of 0% from today's $13.56. Price action looks broadly range-bound.
Kazia Therapeutics Limited's 2027 outlook centres on $14.98, within a $11.58 to $20.70 range. That is up +10% on the projected 2026 average. That marks a +10% change versus current levels. A consolidation phase looks the most probable path here.
By 2028, KZIA could reach as high as $22.09, with a base case around $15.26 and support toward $11.35 — roughly +13% from $13.56. Price action looks broadly range-bound.
Expect KZIA to range from $14.27 to $29.70 through 2029. The $19.79 average target implies a +46% move from current prices. That is up +30% on the projected 2028 average. Buyers look set to stay in control over this stretch.
The KZIA price prediction for 2030 points to an average of $24.24 (low $16.99, high $37.49) — a potential gain of +79% on today's $13.56. Momentum favours further upside here.
In 2031, KZIA is projected to trade between $18.43 and $42.84, averaging $26.99 — a potential gain of +99% from today's $13.56. That is up +11% on the projected 2030 average. Buyers look set to stay in control over this stretch.
Kazia Therapeutics Limited's 2032 outlook centres on $31.38, within a $20.91 to $51.00 range. That is up +16% on the projected 2031 average. That marks a +131% change versus current levels. Momentum favours further upside here.
By 2033, KZIA could reach as high as $47.93, with a base case around $28.88 and support toward $18.81 — roughly +113% from $13.56. Buyers look set to stay in control over this stretch.
Expect KZIA to range from $18.85 to $50.05 through 2034. The $29.58 average target implies a +118% move from current prices. That is up +2% on the projected 2033 average. Momentum favours further upside here.
The KZIA price prediction for 2035 points to an average of $37.65 (low $23.49, high $64.85) — a potential gain of +178% on today's $13.56. Buyers look set to stay in control over this stretch.
In 2040, KZIA is projected to trade between $31.07 and $101.92, averaging $54.93 — a potential gain of +305% from today's $13.56. That is up +46% on the projected 2035 average. Momentum favours further upside here.
Kazia Therapeutics Limited's 2050 outlook centres on $126.19, within a $59.86 to $260.51 range. That is up +130% on the projected 2040 average. That marks a +831% change versus current levels. Buyers look set to stay in control over this stretch.
Investing $1,000 in KZIA today (≈ 73.746313 KZIA) could be worth
$9,306.38
+$8,306.38 (+831%) by 2050 · US Dollar
Based on the average projected KZIA price of $126.19 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in KZIAwould be worth at today's price.
$1,000 invested in KZIA on Jul 10, 2025 (≈ 96.5251 KZIA) would be worth
$1,308.88
+$308.88 (+30.9%) today · 1.31× · US Dollar
Based on a KZIA entry price of $10.36 vs. today's $13.56.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $13.25 | $1,023.4 | +2.3% |
| 1 month ago | $11.5 | $1,179.13 | +17.9% |
| 3 months ago | $8.82 | $1,537.42 | +53.7% |
| 6 months ago | $6.44 | $2,105.59 | +110.6% |
| 1 year ago | $10.36 | $1,308.88 | +30.9% |
| All time (5.0y) ago | $465 | $29.16 | -97.1% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our KZIA forecast.
Our base-case forecast reaches $27.00 around 2032.
Implied market cap at $27.00: $308.53M
The multi-year forecast points to meaningful upside, with 2030 showing an average price of $31.83 and a max of $49.88, for an ROI of 140.3 and bullish sentiment. The 2040 forecast calls for an average of $95.12 and a max of $179.84, for an ROI of 617.9, with bullish sentiment. By 2050 the average is projected at $238.39 with a max of $502.95 and an ROI of 1699.2, continuing the bullish trajectory.
The 2026 forecast is neutral, with an average of $13.25, a min of $5.00, a max of $17.68, and an ROI of 0, while the outlook remains bullish in subsequent years. These figures suggest substantial upside potential but are estimates and carry uncertainty and risk.
Tap a question to reveal the answer.
The 2030 forecast shows an average price of $31.83, with a min of $22.03 and a max of $49.88, and an ROI of 140.3, with bullish sentiment.
The 2026 forecast is neutral with an average of $13.25, a min of $5.00, a max of $17.68, and an ROI of 0, while longer horizons show bullish sentiment and rising prices.
The 2031 max listed is $59.09, while the 2032 max is $71.82, indicating the potential to exceed $60 by 2032 under the forecast.
The current price is $13.25 per share and the market capitalization is $151.41M, with a market rank of 3910.
For 2040, the average is $95.12 with a max of $179.84 and an ROI of 617.9, bullish; for 2050, the average is $238.39 with a max of $502.95 and an ROI of 1699.2, bullish.
Kazia Therapeutics Limited Community Discussion
0Share your Kazia Therapeutics Limited price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.